Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioNexus Gene LabBGLC 58 Quick Ratio is 5.69 as of Mar. 2026, which is 65% above its 10-year median of 3.44. GuruFocus rates BGLC with a GF Score™ of 58/100 and a GF Value™ of $2.17 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 1,606 Chemicals companies, BioNexus Gene Lab ranks better than 92.09% on this metric.
BioNexus Gene Lab has a quick ratio of 5.69. It generally indicates good short-term financial strength.
The historical rank and industry rank for BioNexus Gene Lab's Quick Ratio or its related term are showing as below:
BGLC'
s Quick Ratio Range Over the Past 10 Years
Min: 2.01 Med: 3.44 Max: 20.37
Current: 5.69
During the past 8 years, BioNexus Gene Lab's highest Quick Ratio was 20.37. The lowest was 2.01. And the median was 3.44.
BGLC's Quick Ratio is ranked better than 92.09% of 1606
companies
in the Chemicals industry
Industry Median: 1.375
vs BGLC: 5.69
BioNexus Gene Lab (NAS:BGLC) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
BioNexus Gene Lab Quick Ratio Related Terms
BioNexus Gene Lab Quick Ratio Historical Data
* Premium members only.
The historical data trend for BioNexus Gene Lab's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Specialty Chemicals subindustry, BioNexus Gene Lab's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNexus Gene Lab Quick Ratio vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, BioNexus Gene Lab's Quick Ratio distribution charts can be found below:
* The bar in red indicates where BioNexus Gene Lab's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
BioNexus Gene Lab's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioNexus Gene Lab (BGLC) has a Quick Ratio of 5.69 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on BioNexus Gene Lab and its competitors. This is 65% above median its historical median of 3.44. Over the past decade, BioNexus Gene Lab's Quick Ratio has ranged from 2.01 to 20.37. According to the industry distribution chart, BioNexus Gene Lab ranks #127 out of 1606 companies in the Chemicals industry, placing it in the top 7.9%.
Is BioNexus Gene Lab's Quick Ratio too high?
BioNexus Gene Lab's current Quick Ratio of 5.69 is 65% above median its 10-year median of 3.44. Over the past 10 years, this metric has ranged from a low of 2.01 to a high of 20.37. The Chemicals industry median Quick Ratio is 1.38. BioNexus Gene Lab's value of 5.69 is 313.8% above this industry median. Based on the distribution chart, BioNexus Gene Lab ranks #127 out of 1606 companies in the Chemicals industry, which is in the top quartile — a strong position relative to peers. Overall, BioNexus Gene Lab has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioNexus Gene Lab's Quick Ratio compare to QGAI and VYST?
According to the Chemicals industry distribution chart, BioNexus Gene Lab ranks #127 out of 1606 companies for Quick Ratio. This places BioNexus Gene Lab in the top 8% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 1.38. BioNexus Gene Lab's value of 5.69 is 313.8% above this benchmark. Historically, BioNexus Gene Lab's own Quick Ratio has ranged from 2.01 to 20.37 over the past decade. While the company's 10-year median is 3.44 vs. the industry median of 1.38, BioNexus Gene Lab has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Chemicals company?
The median Quick Ratio among Chemicals companies is 1.38, based on 1,606 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioNexus Gene Lab's current Quick Ratio of 5.69 is 313.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on BioNexus Gene Lab and its competitors. For the Chemicals industry, the median Quick Ratio is 1.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioNexus Gene Lab's current Quick Ratio is 5.69, which is 65% above median its own 10-year median of 3.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNexus Gene Lab stock overvalued right now?
Based on GuruFocus' analysis, BioNexus Gene Lab (BGLC) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.17, compared to a current price of $1.68 — trading 22.6% below its estimated fair value. The current Quick Ratio is 5.69, which is 65% above median its 10-year median of 3.44 and 313.8% above the Chemicals industry median of 1.38. BioNexus Gene Lab's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For BioNexus Gene Lab (BGLC), the current Quick Ratio is 5.69 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioNexus Gene Lab (BGLC) Overvalued in 2026?
Based on GuruFocus' analysis, BioNexus Gene Lab stock appears to be undervalued.
The current stock price of $1.68 is trading 22.6% below its estimated GF Value™ of $2.17.
GuruFocus considers BioNexus Gene Lab to be Modestly Undervalued.
Key valuation signals for BGLC:
Quick Ratio: 5.69 (65% above median its 10-year median of 3.44)
GF Value™: $2.17 vs. price of $1.68 (22.6% below fair value)
Industry Position: 313.8% above the Chemicals median (#127 of 1606)
No single metric tells the full story. See the BGLC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.
58GF Score
Get the complete analysis for BGLC
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLC has been successfully added to your 
